Interchange Capital Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

Interchange Capital Partners’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,646	Closed	-$36.9K	–	268
2024 Q3	$36.9K	Buy	+19,646	New	+$77.6K	0.01%	270
2023 Q2	–	Sell	-11,413	Closed	-$108K	–	154
2023 Q1	$108K	Buy	+11,413	New	+$120K	0.06%	210
2021 Q4	–	Sell	-16,420	Closed	-$145K	–	155
2021 Q3	$145K	Buy	16,420 +5,000	+44%	+$34.8K	0.24%	96
2021 Q2	$90K	Sell	11,420 -13,000	-53%	-$102K	0.14%	103
2021 Q1	$186K	Hold	24,420	–	–	0.1%	227
2020 Q4	$190K	Buy	+24,420	New	+$265K	0.1%	222

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Interchange Capital Partners's ATNM Position: Q4 2024 in Review

Interchange Capital Partners sold out of Actinium Pharmaceuticals (ATNM) in Q4 2024, closing a stake of 19,646 shares — an estimated $36.9K sold.

Interchange Capital Partners first reported a position in ATNM in Q4 2020 and held it in 6 quarters. The position peaked at $190K in Q4 2020. 69 funds tracked by Wall St. Rank hold ATNM as of Q4 2024.

Interchange Capital Partners reported no remaining Actinium Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Interchange Capital Partners sold 19,646 Actinium Pharmaceuticals shares in Q4 2024, an estimated $36.9K.
Interchange Capital Partners first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Interchange Capital Partners's Actinium Pharmaceuticals position peaked at $190K in Q4 2020.
69 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2024.

Based on Interchange Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.